Aktis Oncology has announced U.S. FDA clearance of Investigational New Drug (IND) applications for its novel radiopharmaceutical candidate AKY-2519, enabling progression to a Phase 1b clinical trial expected to begin in mid-2026.
AKY-2519 is a miniprotein radioconjugate designed to target B7-H3, a protein expressed across multiple solid tumors. The therapy delivers actinium-225, a highly potent alpha-emitting radioisotope, directly to tumor cells, aiming to maximize anti-tumor activity while limiting exposure to normal tissues.
This milestone reflects Aktis’ broader strategy to expand the applicability of targeted radiopharmaceuticals to tumor types that have historically been difficult to treat with conventional approaches.
A Platform Designed for Precision and Penetration
Aktis’ proprietary miniprotein radioconjugate platform is engineered to achieve deep tumor penetration, efficient internalization, and sustained retention within cancer cells, while clearing rapidly from healthy tissues.
An important feature of this platform is its dual capability: imaging isotopes can first be used to confirm tumor targeting and biodistribution, followed by therapeutic isotopes for treatment. This approach supports a more personalized and controlled delivery of radiation therapy.
Pipeline Momentum and Upcoming Milestones
In parallel with AKY-2519, the company is advancing AKY-1189, a Nectin-4–targeting radioconjugate currently in a Phase 1b trial across multiple tumor types, including urothelial, breast, colorectal, cervical, head and neck, and lung cancers.
The company anticipates several key milestones over the next year, including initial imaging and dosimetry data for AKY-2519 in 2026 and early clinical data readouts for AKY-1189 in 2027.
These developments position Aktis among a growing group of companies advancing next-generation radiopharmaceuticals as a scalable precision oncology strategy.
Why This Matters for Lung Cancer
The relevance of this development for lung cancer lies in the biology of B7-H3 and the limitations of current treatment strategies. B7-H3 is expressed in non-small cell lung cancer and has been associated with tumor progression and immune evasion, making it an attractive therapeutic target.
Unlike mutation-driven therapies that apply only to selected patient subgroups, B7-H3–targeted approaches may extend treatment options to a broader population of patients with lung cancer, including those without actionable genomic alterations.
In addition, radiopharmaceutical delivery of alpha-emitting isotopes such as actinium-225 introduces a mechanism that is independent of traditional resistance pathways seen with targeted therapy or immunotherapy. This could be particularly relevant in advanced or treatment-refractory lung cancer, where new strategies are urgently needed.
Looking Ahead
With IND clearance secured, the initiation of clinical trials for AKY-2519 will be a critical next step in evaluating the safety, biodistribution, and early efficacy of this approach.
As radiopharmaceuticals continue to evolve, platforms like Aktis’ may contribute to redefining how targeted therapies are delivered across a range of solid tumors, including lung cancer.